Literature DB >> 27383915

Rheumatoid arthritis: Glucocorticoid therapy and body composition.

Frank Buttgereit1, Gerd R Burmester1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27383915     DOI： 10.1038/nrrheum.2016.114

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

Review 1.  Rheumatoid cachexia and cardiovascular disease.

Authors:  Gregory D Summers; Giorgos S Metsios; Antonios Stavropoulos-Kalinoglou; George D Kitas
Journal:  Nat Rev Rheumatol       Date:  2010-07-20       Impact factor: 20.543

2.  The short-term effects of two high-dose, step-down prednisolone regimens on body composition in early rheumatoid arthritis.

Authors:  Nicole P C Konijn; Lilian H D van Tuyl; Maarten Boers; Peter M van de Ven; Debby den Uyl; Marieke M Ter Wee; Pit Kerstens; Alexandre E Voskuyl; Dirkjan van Schaardenburg; Willem F Lems; Michael T Nurmohamed
Journal:  Rheumatology (Oxford)       Date:  2016-05-31       Impact factor: 7.580

3.  Validity and reliability of a 4-compartment body composition model using dual energy x-ray absorptiometry-derived body volume.

Authors:  Abbie E Smith-Ryan; Meredith G Mock; Eric D Ryan; Gena R Gerstner; Eric T Trexler; Katie R Hirsch
Journal:  Clin Nutr       Date:  2016-05-15       Impact factor: 7.324

4.  The timing of glucocorticoid administration in rheumatoid arthritis.

Authors:  N G Arvidson; B Gudbjörnsson; A Larsson; R Hällgren
Journal:  Ann Rheum Dis       Date:  1997-01       Impact factor: 19.103

Review 5.  Clocking in: chronobiology in rheumatoid arthritis.

Authors:  Frank Buttgereit; Josef S Smolen; Andrew N Coogan; Christian Cajochen
Journal:  Nat Rev Rheumatol       Date:  2015-03-24       Impact factor: 20.543

6.  Cachexia in rheumatoid arthritis.

Authors:  Joseph Walsmith; Ronenn Roubenoff
Journal:  Int J Cardiol       Date:  2002-09       Impact factor: 4.164

7.  Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

Authors:  M C van der Goes; J W G Jacobs; M Boers; T Andrews; M A M Blom-Bakkers; F Buttgereit; N Caeyers; E H Choy; M Cutolo; J A P Da Silva; L Guillevin; M Holland; J R Kirwan; J Rovensky; K G Saag; G Severijns; S Webber; R Westhovens; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2009-09-17       Impact factor: 19.103

8.  The effect of disease activity on fat-free mass and resting energy expenditure in patients with rheumatoid arthritis versus noninflammatory arthropathies/soft tissue rheumatism.

Authors:  Anwar Arshad; Rozita Rashid; Kim Benjamin
Journal:  Mod Rheumatol       Date:  2007-12-20       Impact factor: 3.023

9.  Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Ann-Charlotte Elkan; Niclas Håkansson; Johan Frostegård; Tommy Cederholm; Ingiäld Hafström
Journal:  Arthritis Res Ther       Date:  2009-03-10       Impact factor: 5.156

Review 10.  Glucocorticoids and chronotherapy in rheumatoid arthritis.

Authors:  Maurizio Cutolo
Journal:  RMD Open       Date:  2016-03-18
  10 in total
  2 in total

1.  Neglected extra-articular manifestations in rheumatoid arthritis patients with normal body mass index: reduced skeletal muscle overlapping overfat.

Authors:  Jian-Zi Lin; Chu-Tao Chen; Jian-Da Ma; Ying-Qian Mo; Qian-Hua Li; Le-Feng Chen; Ze-Hong Yang; Wan-Mei Cheng; Xiao-Ling He; Dong-Hui Zheng; Lie Dai
Journal:  Ther Adv Chronic Dis       Date:  2020-11-27       Impact factor: 5.091

2.  Factors Associated With Low Lean Mass in Early Rheumatoid Arthritis: A Cross- Sectional Study.

Authors:  Raili Müller; Mart Kull; Kaja Põlluste; Annika Valner; Margus Lember; Riina Kallikorm
Journal:  Medicina (Kaunas)       Date:  2019-11-08       Impact factor: 2.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.